Provided by Tiger Trade Technology Pte. Ltd.

Kazia Therapeutics Limited

5.79
+0.17003.02%
Post-market: 5.790.00000.00%19:19 EST
Volume:102.39K
Turnover:600.86K
Market Cap:65.64M
PE:-0.47
High:6.11
Open:5.94
Low:5.71
Close:5.62
52wk High:17.40
52wk Low:2.86
Shares:11.34M
Float Shares:10.58M
Volume Ratio:0.74
T/O Rate:0.97%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-12.3849
EPS(LYR):-12.3849
ROE:-3891.64%
ROA:-64.28%
PB:-11.25
PE(LYR):-0.47

Loading ...

Kazia Therapeutics Ltd - Plans First-in-Human Clinical Trials for Ndl2 in 2027

THOMSON REUTERS
·
Jan 30

Kazia Therapeutics Ltd - Ndl2 Shows Reversal of Immune Exhaustion and Enhanced Anti-Tumor Activity

THOMSON REUTERS
·
Jan 30

Kazia Therapeutics Announces Compelling Preclinical and Translational Data for Nuclear Pd-L1 Degrader (Ndl2)

THOMSON REUTERS
·
Jan 30

Kazia Therapeutics Unveils Promising Preclinical Data for Nuclear PD-L1 Degrader

Reuters
·
Jan 30

Analysts Conflicted on These Healthcare Names: Korro Bio (KRRO), Kazia Therapeutics (KZIA) and AbbVie (ABBV)

TIPRANKS
·
Jan 28

Four new option listings and one option delisting on January 28th

TIPRANKS
·
Jan 28

Kazia Therapeutics Reports Early Positive Responses for Paxalisib in Phase 1b Trial for Metastatic Triple-Negative Breast Cancer

Reuters
·
Jan 28

Kazia Therapeutics Ltd - to Activate Two Additional Clinical Sites by April 2026

THOMSON REUTERS
·
Jan 27

Kazia Therapeutics Reports Encouraging Preliminary Clinical Responses in Ongoing Phase 1B Study of Paxalisib in Late-Stage Metastatic Triple-Negative Breast Cancer

THOMSON REUTERS
·
Jan 27

Kazia Therapeutics Ltd - Targets Enrollment of 12 Tnbc Patients by End 2026 & Topline Data Readout in Early 2027

THOMSON REUTERS
·
Jan 27

Kazia Therapeutics Ltd - Paxalisib Shows Favorable Safety Profile at 30 Mg Daily Dose

THOMSON REUTERS
·
Jan 27

Kazia Therapeutics Ltd - to Date, Three Tnbc Patients Show Clinical Responses to Paxalisib

THOMSON REUTERS
·
Jan 27

Top Premarket Gainers

MT Newswires Live
·
Jan 05

NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 03:45 PM

Reuters
·
Jan 03

BRIEF-Kazia Therapeutics Regains Full Nasdaq Listing Compliance

Reuters
·
Dec 22, 2025

Kazia Therapeutics Raises $50 Million in Private Placement

Reuters
·
Dec 22, 2025

Kazia Therapeutics Limited : H.c. Wainwright Raises Target Price to $18 From $13

THOMSON REUTERS
·
Dec 12, 2025

Kazia Therapeutics Reports Paxalisib Shows Tumor Shrinkage and Immune Reinvigoration in Advanced Breast Cancer Trial

Reuters
·
Dec 10, 2025

What's Going On With Cancer Firm Kazia Therapeutics

Benzinga
·
Dec 03, 2025

BRIEF-Kazia Therapeutics Announces Pricing Of $50.0 Million Private Placement Of Equity Securities

Reuters
·
Dec 02, 2025